AstraZeneca Pharma India Recommends Final Dividend of ₹36/Share

AstraZeneca Pharma India Ltd announced its Board of Directors has recommended a final dividend of ₹36 per share for the financial year 2025-26. This recommendation is subject to shareholder approval at the 47th Annual General Meeting scheduled for August 10, 2026. The record date for determining dividend entitlement is July 31, 2026. The company also detailed the tax deduction at source (TDS) procedures for the dividend, which will be taxable in the hands of shareholders from FY2020-21 onwards. Specific TDS rates and documentation requirements are outlined for resident and non-resident shareholders, including provisions for PAN holders, non-PAN holders, and those eligible for Double Tax Avoidance Treaty (DTAA) benefits.